B. Riley Issues Pessimistic Forecast for PDS Biotechnology (NASDAQ:PDSB) Stock Price

PDS Biotechnology (NASDAQ:PDSB) had its price target reduced by B. Riley from $9.00 to $7.00 in a report issued on Monday,Benzinga reports. B. Riley currently has a buy rating on the stock. B. Riley also issued estimates for PDS Biotechnology’s Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($1.12) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.52) EPS and FY2028 earnings at ($1.77) EPS.

A number of other analysts have also weighed in on PDSB. Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. StockNews.com lowered shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 9th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research note on Friday, November 15th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, PDS Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Price Performance

NASDAQ:PDSB opened at $2.15 on Monday. The firm has a market capitalization of $80.43 million, a price-to-earnings ratio of -1.85 and a beta of 1.93. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. The business has a 50 day simple moving average of $3.04 and a 200-day simple moving average of $3.16. PDS Biotechnology has a 1 year low of $1.53 and a 1 year high of $6.68.

Institutional Trading of PDS Biotechnology

A number of institutional investors have recently modified their holdings of PDSB. Inspirion Wealth Advisors LLC lifted its position in PDS Biotechnology by 1.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock valued at $1,054,000 after acquiring an additional 4,917 shares during the last quarter. Tempus Wealth Planning LLC purchased a new position in shares of PDS Biotechnology in the second quarter worth about $55,000. Ground Swell Capital LLC purchased a new stake in PDS Biotechnology in the second quarter valued at approximately $67,000. Vontobel Holding Ltd. increased its holdings in PDS Biotechnology by 233.3% in the 3rd quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock worth $153,000 after buying an additional 28,000 shares during the period. Finally, Geode Capital Management LLC lifted its stake in PDS Biotechnology by 9.8% during the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after acquiring an additional 37,142 shares during the period. 26.84% of the stock is currently owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.